Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Publications

Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM.  Selective tropism of seneca valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 2013; 105:1059-65. 

Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SNH, Aziz K, Cho Y-J, Tran PT, Rudin CM.  Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene driven non-small cell lung cancer. Mol Cancer Res 2013; 11: 329-38.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH, Beachy PA, Rudin CM.  Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013; 23:23-34.

Rudin CM, Durinck S, Stawiski E, Poirier JT, Modrusan Z, Shames D, Bergbower EA, Guan Y, Shin J, Guillory J, Sanchez Rivers C, Foo C, Dhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal B, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S.  Comprehensive genomic and expression profiling of small cell lung cancers identifies SOX2 as a frequently amplified gene regulating proliferation and correlating with clinical stage. Nat Genet 2012; 44:1111-6.

Aftab BT, Dobromilskaya I, Liu JO, Rudin CM.  Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011; 71:6764-72.